$Doxorubicin (DXR, 14-Hydroxydaunomycin, Adriamycin, Adriacin, Adriblastin, Caelyx, Dox, Doxil, \nFarmiblastina, FI 106, K 1039, KW 125, NSC 123127 \n)$

Supplier:

Cat no: D9099-45

Doxorubicin (DXR, 14-Hydroxydaunomycin, Adriamycin, Adriacin, Adriblastin, Caelyx, Dox, Doxil, \nFarmiblastina, FI 106, K 1039, KW 125, NSC 123127 \n)

Doxorubicin is the most extensively studied of a family of highly fluorescent anthracycline antibiotics produced by several Streptomyces species, first reported in 1967 and later approved for human therapeutic use as an antitumor agent for the treatment of a wide range of cancers. Doxorubicin has also been reported to exhibit anti-HIV and antibacterial activity. The mode of action of doxorubicin is thought to be due to intercalation of DNA and inhibition of nucleic acid synthesis. \n\nApplications: \nSuitable for use in ELISA, Immunohistochemistry and Functional Applications. Other applications have not been tested. \n\nRecommended Dilutions: \nFunctional Applications: In vivo antidotic effect\nOptimal dilutions to be determined by the researcher. \n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

D9099-45

Size

100ug

Applications

ELISA, IHC

Hosts

Mouse

Form

Supplied as a liquid in 150mM sodium chloride, pH 7.4, 0.02% sodium azide.

P Type

Mab

Purity

Purified

Isotype

IgG2

References

1. Monoclonal antibodies against doxorubicin: A. Balsari, et al.; Int. J. Cancer 42, 798 (1988) Abstracte: A. Balsari, et al.; Anticancer Res. 10, 129 (1990) 2. A. Balsari, et al.; Int. J. Cancer 47, 889 (1991) 3. A. Sardini, et al.; Int. J. Cancer 50, 617 (1992) 4. : A.L. Balsari, et al.; FASEB J. 8, 226 (1994) 5.: D. Morelli, et al.; Cell Biophys. 24-25, 119 (1994) 6. i, et al.; Scand. J. Immunol. 39, 453 (1994) 7. D. Morelli, et al.; Cancer Res. 56, 2082 (1996) 8. R. Cece, et al.; Lab. Invest. 75, 601 (1996) 9. Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice: D. Morelli, et al.; Br. J. Cancer 75, 656 (1997) 10. A. Balsari, et al.; Br. J. Cancer 85, 1964 (2001) 11. M. Campiglio, et al.; Int. J. Cancer 105, 568 (2003)

Additional Info

Recognizes anthracycline compounds including doxorubicin analogs and derivatives.